Ustekinumab for psoriasis and psoriatic arthritis in adolescents with 22q11.2 deletion syndrome
-
Published:2023-12
Issue:12
Volume:11
Page:3799-3801
-
ISSN:2213-2198
-
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
-
language:en
-
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice
Author:
Yi Belina Y.ORCID,
Kamath Sonia,
Luu Minnelly,
Cidon Michal,
Braskett Melinda
Subject
Immunology and Allergy
Reference9 articles.
1. Relationship between severity of T cell lymphopenia and immune dysregulation in patients with DiGeorge syndrome (22q11.2 deletions and/or related TBX1 mutations): a USIDNET study;Deshpande;J Clin Immunol,2021
2. Pathophysiology, clinical presentation, and treatment of psoriasis: a review;Armstrong;JAMA,2020
3. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents);Baddley;Clin Microbiol Infect,2018
4. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial;McInnes;Lancet,2013
5. Adverse events in methotrexate-treated rheumatoid arthritis patients;Sandoval;Br J Rheumatol,1995